日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma

对中国新诊断或复发/难治性多发性骨髓瘤患者使用达雷妥尤单抗治疗方案的治疗模式、疗效和安全性进行真实世界分析

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-13925-3
Wang, Luqun; Yang, Wei; Wang, Yafei; Niu, Ting; Fu, Rong; Zhong, Yuping; Qian, Wenbin; Ding, Kaiyang; Sun, Kai; Liu, Hong; Fang, Baijun; Liu, Hui; Li, Yanhui; Yang, Yishen; Zhuo, Jianmin; Chen, Xi; Cui, Canchan; Lu, Jin
多发性骨髓瘤
骨髓瘤
发表日期：2025
文献求助 收藏

Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study

在不适合移植的亚洲新诊断多发性骨髓瘤患者中，达雷妥尤单抗、硼替佐米、美法仑和泼尼松联合治疗与单用硼替佐米、美法仑和泼尼松治疗的疗效比较：3期OCTANS研究的最终分析

期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-024-05958-8
Fu, Weijun; Bang, Soo-Mee; Huang, Honghui; Kim, Kihyun; Li, Wei; An, Gang; Lee, Je-Jung; Cai, Zhen; Jin, Jie; Wang, Yafei; Chim, Chor Sang; Carson, Robin; Liu, Rui; Zhao, Man; Chen, Xi; Cui, Canchan; Hou, Jian; Wang, Jianxiang
多发性骨髓瘤
骨髓瘤
发表日期：2025
文献求助 收藏

Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study

在不适合移植的新诊断多发性骨髓瘤患者中，达雷妥尤单抗、硼替佐米、美法仑和泼尼松联合治疗与单用硼替佐米、美法仑和泼尼松治疗相比，其健康相关生活质量的改善情况：3期OCTANS研究分析

期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-025-06303-3
Fu, Weijun; Bang, Soo-Mee; Huang, Honghui; Kim, Kihyun; Li, Wei; An, Gang; Lee, Je-Jung; Cai, Zhen; Jin, Jie; Wang, Yafei; Chim, Chor Sang; Carson, Robin; Liu, Rui; Zhao, Man; Chen, Xi; Cui, Canchan; Hou, Jian; Wang, Jianxiang
多发性骨髓瘤
骨髓瘤
发表日期：2025
文献求助 收藏

Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study

更正：在不适合移植的亚洲新诊断多发性骨髓瘤患者中，达雷妥尤单抗、硼替佐米、美法仑和泼尼松联合治疗与单用硼替佐米、美法仑和泼尼松治疗的疗效比较：OCTANS 3期研究的最终分析

期刊:Annals of Hematology
影响因子:2.4
doi:10.1007/s00277-024-06020-3
Fu, Weijun; Bang, Soo-Mee; Huang, Honghui; Kim, Kihyun; Li, Wei; An, Gang; Lee, Je-Jung; Cai, Zhen; Jin, Jie; Wang, Yafei; Chim, Chor Sang; Carson, Robin; Liu, Rui; Zhao, Man; Chen, Xi; Cui, Canchan; Hou, Jian; Wang, Jianxiang
多发性骨髓瘤
骨髓瘤
发表日期：2024
文献求助 收藏